Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Aviptadil
BIOLOGICAL
3 trials
Sponsors
QuantumLeap Healthcare Collaborative
, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
COVID-19
Covid19
Phase 2
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Active, not recruiting
NCT04488081
QuantumLeap Healthcare Collaborative
COVID-19
Start: 2020-07-31
End: 2030-07-31
Target: 1500
Updated: 2026-03-16
Phase 3
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Completed
NCT04843761
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Start: 2021-04-20
End: 2022-11-20
Updated: 2025-10-24
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Completed
NCT06729606
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Start: 2021-04-20
End: 2022-11-20
Updated: 2025-10-09
Related Papers
Simulation-Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case Studies.
2026-01-01
1 citations
Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.
2025-10-29
Anti-CD14 Treatment in Patients With Severe COVID-19 Clinical and Biological Effects in a Phase 2 Randomized Open-Label Adaptive Platform Clinical Trial
CHEST Critical Care
2024-12-09
2 citations
Phosphatidylethanol measures in patients with severe <scp>COVID</scp>‐19‐associated respiratory failure identify a subset with alcohol misuse
Alcohol Clinical and Experimental Research
2024-11-26
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
2023-06-19
13 citations
Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.
2023-03-03
18 citations
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations
BMJ Open
2022-06-01
25 citations